AK-119 / Akaal Pharma - LARVOL DELTA

Akaal Pharma Pty Ltd has received approval for a Phase-2 clinical trial involving patients with atopic dermatitis (EIN News) - "Akaal Pharma Pty Limited (Akaal) today announced that it has received regulatory approval from Drugs Controller General of India (DCGI) for a Phase-2 clinical study involving 150 participants to further evaluate the safety, tolerability, and efficacy of a topical formulation of AK-119 in atopic dermatitis participants with pruritus. AK-119 is a differentiated Spingosine-1-Phosphate receptor subtype-1 (S1P1) modulator. This study follows the successful Phase-1 study on atopic dermatitis and psoriasis patients that showed AK-119 to be safe, well tolerated with clear signals of efficacy relieving inflammation and disease score with non-significant systemic exposure via topical treatment. It is anticipated the Phase-2 clinical study will begin dosing patients in Q3 of 2023."

New P2 trial • Atopic Dermatitis • Immunology

Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=87 | Recruiting | Sponsor: Akeso | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Oncology • Solid Tumor